Evaluation of deladroxate as a monthly contraceptive injection.
Karim
M
M
El-mahgoub
S
S
El-ganzoury
B
B
Ammar
R
R
Yaseen
S
S
Fikri
F
F
D000463:Algestone Acetophenide; D001835:Body Weight; D003267:Contraception; D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D003278:Contraceptives, Oral, Hormonal; D004717:Endometrium; D004997:Ethinyl Estradiol; D005193:Family Planning Services; D007267:Injections; D008099:Liver; D008597:Menstrual Cycle; D008598:Menstruation; D010053:Ovary; D018873:Pregnancy Rate; D012102:Reproductive Control Agents
D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D003278:Contraceptives, Oral, Hormonal; D012102:Reproductive Control Agents; D004997:Ethinyl Estradiol; D000463:Algestone Acetophenide
Algestone Acetophenide--side effects; Body Weight; Contraception; Contraceptive Agents; Contraceptive Agents, Estrogen--side effects; Contraceptive Agents, Female; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--side effects; Contraceptive Methods--side effects; Endometrial Effects; Ethinyl Estradiol--side effects; Family Planning; Hepatic Effects; Injectables--side effects; Menstrual Cycle; Menstruation; Ovarian Effects; Pregnancy Rate; Reproductive Control Agents